This module uses fundamental data of Royalty Pharma to approximate the value of its Beneish M Score. Royalty Pharma M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Royalty Pharma Piotroski F Score and Royalty Pharma Altman Z Score analysis.
Royalty
Beneish M Score
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Total Cashflows From Investing Activities
Capital Expenditures
Total Cash From Financing Activities
Change To Inventory
Total Cash From Operating Activities
Other Cashflows From Investing Activities
Change To Liabilities
Other Cashflows From Financing Activities
Sale Purchase Of Stock
Change In Cash
Depreciation
Change To Operating Activities
Net Income
Change To Netincome
End Period Cash Flow
Investments
Net Borrowings
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Dividends Paid
Change To Account Receivables
Stock Based Compensation
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Accounts Payable
Cash
Other Assets
Common Stock Shares Outstanding
Short Term Investments
Inventory
Other Current Assets
Total Liab
Treasury Stock
Common Stock
Property Plant Equipment
Intangible Assets
Net Tangible Assets
Retained Earnings
Total Current Assets
Short Long Term Debt Total
Net Debt
Non Current Assets Total
Non Currrent Assets Other
Long Term Debt
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Long Term Debt Total
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Net Invested Capital
Long Term Investments
Short Long Term Debt
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Short Term Debt
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Capital Surpluse
Interest Expense
Total Revenue
Research Development
Cost Of Revenue
Selling General Administrative
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Depreciation And Amortization
Other Operating Expenses
Ebitda
Reconciled Depreciation
Minority Interest
Non Operating Income Net Other
Probability Of Bankruptcy
At this time, Royalty Pharma's Debt Equity Ratio is fairly stable compared to the past year. Debt Ratio is likely to rise to 0.52 in 2024, whereas Long Term Debt Total is likely to drop slightly above 6.9 B in 2024. At this time, Royalty Pharma's ROE is fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.09 in 2024, whereas Price To Sales Ratio is likely to drop 5.07 in 2024.
At this time, it appears that Royalty Pharma Plc is an unlikely manipulator. The earnings manipulation may begin if Royalty Pharma's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Royalty Pharma executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Royalty Pharma's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Royalty Pharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Royalty Pharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Royalty Pharma in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Royalty Pharma's degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Royalty Pharma. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Royalty Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Royalty Pharma's managers, analysts, and investors.
Environmental
Governance
Social
About Royalty Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Royalty Pharma Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Royalty Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Royalty Pharma Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.